Next Weight Loss Drugs Pipeline (2026): Retatrutide 28.7%, CagriSema 22.7%, MariTide Monthly
CagriSema, retatrutide, MariTide and survodutide remain investigational in the US. Their trial percentages describe different populations and analyses, not a head-to-head ranking. Foundayo is already FDA-approved.
Here is what each result and announced milestone actually means.
By GLP-1 Picks, an independent comparison publication. Sources linked below. Our editorial policy.
Summarize this article with

In this article
- 01How do the pipeline drugs compare?
- 02CagriSema (Novo Nordisk): semaglutide plus an amylin analog
- 03Retatrutide (Eli Lilly): the triple agonist
- 04MariTide (Amgen): a once-monthly injection
- 05Survodutide (Boehringer Ingelheim): current Phase 3 evidence
- 06Foundayo (orforglipron, Eli Lilly): approved April 2026
- 07Should you wait for these drugs?
- 08Sources and how to read these results
CagriSema, retatrutide, MariTide and survodutide are investigational medicines, not FDA-approved prescription options. Foundayo, the oral drug orforglipron, has already crossed that boundary: the FDA approved it on April 1, 2026.
This guide separates trial findings, announced development milestones and treatment availability.
The headline percentages are not a ranking. Trials differ in who took part, how long treatment lasted and how they handled people who stopped treatment. A filing or a company's expected decision date is not an approval.
The table below keeps those distinctions beside each result.
Looking for treatment available now? Start with the GLP-1 beginner's guide and current programs.
The Enhance MD, Embody and Hers reviews explain their respective products and payment terms.
A branded drug's trial result does not establish the result of a compounded product.
Keep trial findings separate from treatment access
Investigational medicines and approved options are different. This overview separates their trial findings and development milestones from current prescription access.
Read GLP-1 guides and news →How do the pipeline drugs compare?
Read each result with its population, duration and analysis method. Treatment-policy or treatment-regimen analyses include the effect of treatment interruptions or discontinuation under the study's rules.
Trial-product or efficacy analyses estimate outcomes under continued treatment. They answer different questions; neither is a promised individual result.
| Drug and format | Selected trial result | Who and how long | US status and announced milestone |
|---|---|---|---|
| Foundayo (Lilly), daily oral GLP-1 | 11.2%, treatment-regimen analysis, ATTAIN-1; 36 mg trial formulation | Adults without diabetes; 72 weeks | FDA-approved April 1, 2026; current access and dosing context |
| CagriSema (Novo Nordisk), weekly injection | 20.4% treatment-policy; 22.7% trial-product, REDEFINE 1 | Adults without diabetes; 68 weeks | NDA filed December 2025; Novo expects a decision in Q4 2026, not a guaranteed approval |
| Retatrutide (Lilly), weekly injection | 28.7% at 12 mg, efficacy analysis, TRIUMPH-4 | Adults with obesity or overweight and knee osteoarthritis, without diabetes; 68 weeks | Phase 3; Lilly plans a Q1 2027 filing, not an approval date |
| MariTide (Amgen), monthly injection studied | Up to 19.9%, efficacy analysis, Phase 2 | Adults without type 2 diabetes; 52 weeks | MARITIME-1 and -2 Phase 3 studies ongoing; no FDA approval date given in that update |
| Survodutide (Boehringer Ingelheim), weekly injection | 9.8% at 6 mg versus 3.9% placebo, treatment-regimen analysis, SYNCHRONIZE-2 | Adults with type 2 diabetes and BMI at least 27; 76 weeks | Phase 3 results published October 1, 2026; trial publication is not approval |
CagriSema (Novo Nordisk): semaglutide plus an amylin analog
The CagriSema combination studied in REDEFINE 1 pairs semaglutide 2.4 mg with the amylin analogue cagrilintide 2.4 mg in a once-weekly injection.
The published trial enrolled 3,417 adults without diabetes. For the wider development and filing timeline, see the CagriSema guide.
At 68 weeks, the two analyses gave different estimates. Keep the columns separate when comparing the randomized groups:
| REDEFINE 1 arm | Treatment-policy weight reduction | Trial-product weight reduction |
|---|---|---|
| CagriSema | 20.4% | 22.7% |
| Semaglutide alone | 14.9% | 16.1% |
| Cagrilintide alone | 11.5% | 11.8% |
| Placebo | 3.0% | 2.3% |
REDEFINE 2 studied a different population: 1,206 adults with type 2 diabetes and BMI at least 27.
At 68 weeks, CagriSema's estimated weight reduction was 13.7% under the treatment-policy analysis and 15.7% under the trial-product analysis. These findings concern a separate trial in people with diabetes.
Novo reported REDEFINE 4 on February 23, 2026.
At 84 weeks, the efficacy analysis estimated 23.0% weight reduction with CagriSema versus 25.5% with tirzepatide; the treatment-regimen estimates were 20.2% versus 23.6%.
The open-label trial did not meet its primary noninferiority endpoint. This is a direct comparison, unlike the separate-study figures above.
Novo's September 30 update says the US application was filed in December 2025 and a decision is expected in Q4 2026.
That update gives a quarter, not a specific PDUFA or launch date. The application draws on REDEFINE 1 and 2; the FDA's review determines its outcome.
In REDEFINE 1, gastrointestinal events affected 79.6% of the CagriSema group, 73.8% of the semaglutide group and 39.9% of the placebo group. Most were mild or moderate.
The 39.9% figure is the placebo comparator, not semaglutide.
Retatrutide (Eli Lilly): the triple agonist
Retatrutide activates GIP, GLP-1 and glucagon receptors.
In Lilly's TRIUMPH-4 report, adults with knee osteoarthritis and obesity or overweight, without diabetes, had an estimated 28.7% weight reduction with 12 mg at 68 weeks under the efficacy analysis.
That is the source and population behind the 28.7% headline.
The separate TRIUMPH-1 report estimated 28.3% weight reduction at 80 weeks with 12 mg under the efficacy analysis, versus 25.0% under the treatment-regimen analysis.
The 30.3% result at 104 weeks came from a selected extension for participants with baseline BMI at least 35 who completed and tolerated the main study; it is not the result for every randomized participant.
Safety findings also belong to their trial. TRIUMPH-4 reported dysesthesia, an altered skin sensation, in 20.9% at 12 mg versus 0.7% with placebo.
Lilly's later development update says a Biologics License Application is planned for Q1 2027.
That is a filing plan, not an FDA approval date. The retatrutide guide covers the program in more detail.
MariTide (Amgen): a once-monthly injection
MariTide (maridebart cafraglutide) combines GLP-1 receptor agonism with GIP receptor antagonism in an antibody-peptide conjugate. Amgen is studying monthly or less-frequent dosing.
The Phase 2 report included 465 adults without type 2 diabetes and 127 with it.
At 52 weeks, weight reduction in the groups without diabetes ranged from 16.3% to 19.9% under the efficacy analysis and 12.3% to 16.2% under the treatment-policy analysis.
For the diabetes cohort, the ranges were 12.1% to 17.0% and 8.4% to 12.3%, respectively. These are results across study groups, not the outcome of one settled commercial dose.
Gastrointestinal events were common, mostly mild or moderate.
- •Current stage: Amgen's August 4, 2026 update lists MARITIME-1 and MARITIME-2 as ongoing Phase 3 studies.
- •What remains unproven: monthly dosing is a feature being studied, not evidence that people will necessarily stay on treatment longer.
- •Approval timing: that update does not give an FDA approval date. A trial milestone is not a launch schedule.
Survodutide (Boehringer Ingelheim): current Phase 3 evidence
Survodutide is a glucagon/GLP-1 receptor dual agonist. SYNCHRONIZE-2, published October 1, 2026, studied 752 adults with type 2 diabetes and BMI at least 27.
At 76 weeks, the treatment-regimen analysis estimated 9.8% weight reduction with 6 mg, 8.2% with 3.6 mg and 3.9% with placebo.
This analysis includes the effects of treatment interruption, discontinuation and other obesity therapy under the trial rules.
The earlier Phase 2 study involved adults without diabetes over 46 weeks. Its primary planned-treatment estimate at 4.8 mg was 14.9%, versus 2.8% with placebo.
Different populations, durations and analysis methods mean this is not a direct comparison with SYNCHRONIZE-2. The newer study's gastrointestinal-event rates were 77.7% at 6 mg and 38.6% with placebo.
Foundayo (orforglipron, Eli Lilly): approved April 2026
The FDA approved Foundayo on April 1, 2026 for weight management alongside a reduced-calorie diet and increased activity in eligible adults.
It is an approved oral option, not another investigational row.
Its prescribing information specifies once-daily use with or without food.
In ATTAIN-1, the highest trial formulation, 36 mg, produced an estimated 11.2% weight reduction at 72 weeks under the treatment-regimen analysis, versus 2.1% with placebo.
That trial-formulation strength is not a patient dosing instruction; the marketed tablets have different strengths.
See the Foundayo guide for current access, formulation and payment details, or the Wegovy pill comparison for another approved oral route.
Should you wait for these drugs?
A promising trial or projected FDA decision does not tell you whether to start, stop or switch treatment.
Discuss currently approved options and your circumstances with a prescriber rather than treating a pipeline forecast as a treatment plan.
The beginner's guide separates current prescription choices; Foundayo has its own access and cost guide.
If your next step is evaluating programs, use the cost calculator for a scenario estimate and the program match quiz to organize your shortlist.
Neither confirms eligibility, prescribes treatment or makes an investigational medicine available.
Sources and how to read these results
The table summarizes selected published studies and dated sponsor announcements, not every obesity-development program. Approval status comes from the FDA; development plans come from the named companies and can change.
A sponsor announcement is identified as such. Separate trials are not head-to-head evidence, and none of these percentages predicts an individual's response.
- REDEFINE 1, NEJM, 2025, and REDEFINE 2, NEJM, 2025.
- Novo: REDEFINE 4, February 23, 2026; CagriSema development update, September 30, 2026.
- Lilly: TRIUMPH-4, December 11, 2025; TRIUMPH-1, May 21, 2026; later development and filing update.
- Amgen: MariTide Phase 2, June 23, 2025; Phase 3 program update, August 4, 2026.
- Survodutide Phase 2, 2024; SYNCHRONIZE-2 Phase 3, October 1, 2026.
- FDA: Foundayo approval, April 1, 2026; ATTAIN-1, NEJM; Foundayo prescribing information.
Medical disclaimer: This article is general information, not medical advice. Talk to a licensed clinician before you start, stop or change any medication. Prices and rules can change after the date we checked them.
Affiliate disclosure: Some links in this article are affiliate links. If you join a program through one, we may earn a commission at no extra cost to you.
What the doctors say
Quotes from named doctors and medical bodies, each linked to where they said it. We did not ask for them, and they do not endorse any provider.
“Thanks to the latest advancements in obesity management medications, more physicians and patients are witnessing significant weight reduction beyond what they have seen before. The SURMOUNT-5 head-to-head results demonstrated tirzepatide led to greater weight reduction compared to semaglutide, providing further evidence to support tirzepatide as an effective option for obesity.”
“Patients on both medications experienced substantial weight loss, and we observed no difference in the risk of gastrointestinal adverse events. In addition to effectiveness, factors like medication availability and insurance coverage will likely play a role in deciding which medication to initiate.”
“For more than a million people at high risk of heart attack and stroke, this treatment on the NHS could be life-changing: offering a powerful new way to protect their hearts and improve their health.”
Quotes are general medical commentary about GLP-1 medications, independently sourced and not solicited by GLP-1 Picks. They are not an endorsement of any provider, our provider scores are set solely by our published methodology.




